Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 3:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 690 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Corticosteroids Clear all
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Effectiveness of Corticosteroid vs. Ketorolac Shoulder Injections: A Prospective Double-Blinded Randomized Trial

NCT04115644
View directory record Official record
Conditions
Full Thickness Rotator Cuff Tear, Rotator Cuff Tendinitis
Interventions
Ketorolac, Marcaine (placebo), Kenalog
Drug
Lead sponsor
Michael Khazzam
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Baltimore, Maryland • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Oct 28, 2026, 3:53 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Late Preterm Corticosteroids and Neonatal Hypoglycemia

NCT04869709
View directory record Official record
Conditions
Neonatal Hypoglycemia, Prematurity
Interventions
Betamethasone Sodium Phosphate
Drug
Lead sponsor
University of Southern California
Other
Eligibility
Female only
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 28, 2026, 3:53 PM EDT
Recruiting No phase listed Observational

An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis

NCT06627335
View directory record Official record
Conditions
Pregnancy Related, Atopic Dermatitis
Interventions
Ruxolitinib Cream, TCS
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
14 Years and older · Female only
Enrollment
5,621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Morrisville, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis

NCT02465606
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab, Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Encino, California • Granada Hills, California • Mission Viejo, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 28, 2026, 3:53 PM EDT
Completed No phase listed Observational

Prospective Observational Study on the Incidence of Opportunistic Fungal Infections

NCT05707156
View directory record Official record
Conditions
Pneumocystis Jirovecii Infection, Pneumocystis, Cryptococcosis, Candidiasis, Aspergillosis
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
12,032 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 28, 2026, 3:53 PM EDT
Terminated Phase 4 Interventional Results available

Differential Efficacy of Corticosteroid Solutions for Non-Operative Treatment of Digit Flexor Tenosynovitis

NCT04002037
View directory record Official record
Conditions
Trigger Finger
Interventions
Triamcinolone Acetonide 40mg/mL, Triamcinolone Acetonide 10mg/mL, Dexamethasone 4 mg/ml
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Phase 2Phase 3 Interventional

Neovascular Age Related Macular Degeneration (AMD), Periocular Corticosteroids, and Photodynamic Therapy (PDT)

NCT00305630
View directory record Official record
Conditions
Choroidal Neovascularization, Age-Related Macular Degeneration
Interventions
Periocular injection of triamcinolone acetonide 40mg
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
2
States / cities
Baltimore, Maryland • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 22, 2006 · Synced Oct 28, 2026, 3:53 PM EDT
Recruiting Phase 3 Interventional

A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

NCT06338995
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Interventions
LY3650150, Placebo, Standard therapy for INCS
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Phase 3 Interventional

Randomized Trial of Iontophoresis Versus Injection of Corticosteroids for Lateral Epicondylitis

NCT00257634
View directory record Official record
Conditions
Lateral Epicondylitis, Work Related Injury
Interventions
dexamethasone to injury site
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 27, 2007 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Phase 2 Interventional Results available

Bi 671800 in Asthmatic Patients on Inhaled Corticosteroids

NCT01090024
View directory record Official record
Conditions
Asthma
Interventions
BI 671800, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
Huntington Beach, California • Mission Viejo, California • Stockton, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Phase 2 Interventional Results available

Study of FX006 in Patients With Osteoarthritis of the Knee

NCT01487161
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
FX006, TCA IR
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
40 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Tucson, Arizona • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 28, 2026, 3:53 PM EDT
Completed No phase listed Observational Results available

Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy

NCT04184297
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium and Olodaterol (Tio+Olo), Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
27,190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Oct 28, 2026, 3:53 PM EDT
Recruiting Phase 3 Interventional

Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

NCT03583710
View directory record Official record
Conditions
ENSAT Stage I Adrenal Cortex Carcinoma, ENSAT Stage II Adrenal Cortex Carcinoma, ENSAT Stage III Adrenal Cortex Carcinoma
Interventions
Cisplatin, Etoposide, Mitotane, Quality-of-Life Assessment
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
3
States / cities
Ann Arbor, Michigan • St Louis, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Phase 3 Interventional

Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)

NCT02108860
View directory record Official record
Conditions
Granulomatosis With Polyangiitis (Wegener's), Granulomatosis With Polyangiitis, Wegener's Granulomatosis, ANCA-Associated Vasculitis
Interventions
Abatacept, placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
15 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
10
States / cities
Los Angeles, California • Tampa, Florida • Kansas City, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 28, 2026, 3:53 PM EDT
Completed No phase listed Observational

Predicting Reduction of Hypertension After Adrenalectomy for Primary Aldosteronism: a Multicenter Analysis

NCT04761354
View directory record Official record
Conditions
Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism, Primary Aldosteronism Due to Conn Adenoma
Interventions
Unilateral adrenalectomy
Procedure
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Phase 4 Interventional

Levetiracetam for Neuroprotection Against Corticosteroid-induced Hippocampal Dysfunction: A Proof of Concept Study

NCT00223223
View directory record Official record
Conditions
Memory Loss Associated With Corticosteroid Use, Manic State Associated With Corticosteroid Use
Interventions
Levetiracetam, Keppra
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2011 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Combined PEX, Rituximab and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations

NCT01266317
View directory record Official record
Conditions
IPF
Interventions
Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids
Drug
Lead sponsor
Michael Donahoe
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 28, 2026, 3:53 PM EDT
Terminated Phase 2 Interventional Results available

Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)

NCT00675441
View directory record Official record
Conditions
Graft-versus-Host Disease
Interventions
Lenalidomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Oct 28, 2026, 3:53 PM EDT
Terminated Phase 4 Interventional Results available

Sputum-derived Cellular Targets After Xolair (Omalizumab)

NCT02658877
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States

NCT05329194
View directory record Official record
Conditions
Asthma
Interventions
Tezepelumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
37
States / cities
Mobile, Alabama • Gilbert, Arizona • Long Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 28, 2026, 3:53 PM EDT
Recruiting Phase 3 Interventional

NSAID Injection Versus Corticosteroid Injection for Basilar Thumb Arthritis

NCT05992883
View directory record Official record
Conditions
Thumb Osteoarthritis
Interventions
Ketorolac, Triamcinolone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Steroid-Releasing S8 Sinus Implant for Recurrent Nasal Polyps

NCT01732536
View directory record Official record
Conditions
Chronic Sinusitis, Nasal Polyps
Interventions
S8 Sinus Implant, Sham procedure, Mometasone furoate nasal spray
Drug · Procedure
Lead sponsor
Intersect ENT
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
19
States / cities
Atherton, California • Los Angeles, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2018 · Synced Oct 28, 2026, 3:53 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study to Evaluate the Impact of Obesity on Airway Inflammation and Mechanics in Asthmatics

NCT00615706
View directory record Official record
Conditions
Asthma
Interventions
No intervention
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 23, 2008 · Synced Oct 28, 2026, 3:53 PM EDT
Completed Phase 2 Interventional Results available

Desoximetasone Spray 0.05%, 0.25%; Dose Ranging Study

NCT01018134
View directory record Official record
Conditions
Psoriasis
Interventions
Desoximetasone 0.05% once daily, Desoximetasone 0.05% twice daily, Desoximetasone 0.25% once daily, Vehicle once daily, Vehicle twice daily
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Miami, Florida • Martinez, Georgia • Olathe, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2014 · Synced Oct 28, 2026, 3:53 PM EDT